May 09, 2023 / 03:00PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Welcome to the BofA Healthcare Conference. My name is Geoff Meacham, I'm a senior biopharma analyst here at BofA. And we're happy to kick it off with AbbVie today.
So with me on stage, we have Rob Michael, Vice Chairman and President; Scott Reents, EVP, CFO; Jeff Stewart, EVP, CCO; and then Roopal Thakkar, who is SVP, Development, Regulatory Affairs and CMO. So guys, thanks for coming.
Robert A. Michael - AbbVie Inc. - Vice Chairman & President
Thanks for having us.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystAlways a big crew, right? Rob, I'll kick it off to you. So when we talk about the cadence of this year, you guys have given pretty good specifics on the flow of earnings trough just with respect to the HUMIRA erosion. As you have moved through the year so far, what would you say is kind of better or worse than you thought initially? What are the